Sandoz Picks Hexal’s Hometown For Generics Division Global Headquarters
This article was originally published in The Pink Sheet Daily
Novartis’ generics division will move to Holzkirchen, Germany, the home of Hexal, as part of the integration of that company and U.S-based Eon. Acquisition of the two generic firms is expected to close in the second half of 2005.
You may also be interested in...
Addition of U.S., German companies will make Sandoz the global leader in generic sales, with combined 2004 pro forma revenues of $5.1 bil., Novartis says. Acquisition will enable Sandoz to become the "preferred partner" for "authorized" generic deals and to play a leading role in development of follow-on biologics.
Eon Labs CEO Bernhard Hampl will become head of Sandoz' U.S. operations following Novartis' acquisition of Eon
“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.